
First proposed in 2018, housing scheme in Chandigarh's Sector 53 gets governor's nod
The stalled project—it was first proposed in 2018—will now move forward with updated prices aligned with the current collector rates, effective from April 1.
According to the CHB, the tentative price of a high-income group (HIG) three-bedroom flat has been set at Rs 2.30 crore, marking a 39.39 per cent hike from the earlier estimate of Rs 1.65 crore. A two-bedroom flat in the middle-income group (MIG) category will now cost Rs 1.97 crore, reflecting a 40.71 per cent increase from the previous Rs 1.40 crore. The cost of a flat under the economically weaker sections (EWS) category has been revised to Rs 74 lakh, up 34.34 per cent from Rs 55 lakh.
The scheme, which had faced repeated delays and was even shelved in 2023, saw renewed momentum after an overwhelming response to a fresh demand survey conducted from February 22 to March 3 this year. A total of 7,468 applications were received—5,081 for HIG units, 1,269 for MIG, and 1,118 for EWS flats—indicating strong demand, especially for 3BHK units, which made up nearly 68 per cent of the total applications.
The upcoming project includes 192 HIG units, 100 MIG houses, and 80 EWS flats, to be developed on approximately nine acres of land in Sector 53.
This is the CHB's first major housing scheme since the 2016 launch of 200 two-bedroom flats in Sector 51. An earlier effort in 2020 to revive the scheme had failed to attract buyers, with only 148 applications received against the 492 planned units. The CHB had to cancel the survey and refund the deposits.
However, renewed interest in city real estate and successful auctions of vacant CHB flats encouraged the Board to revisit the plan.
In May 2023, the CHB had approved the construction of 372 flats. But the scheme was again halted in August 2023 by the then UT Administrator Banwarilal Purohit, who deemed it unnecessary, leading to the cancellation of Rs 200 crore worth of construction tenders.
2018: CHB proposes new housing scheme with 492 units
2019: Demand survey initiated
2020: Scheme scrapped due to poor response
May 2023: CHB revives project with 372 flats
Aug 2023: Scheme halted by then UT Administrator Banwarilal Purohit
2025: CHB receives 7,468 applications in latest survey

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
25 minutes ago
- Business Standard
Tata Consumer Products Ltd down for fifth straight session
Tata Consumer Products Ltd is quoting at Rs 1073.7, down 0.29% on the day as on 13:19 IST on the NSE. The stock tumbled 5.38% in last one year as compared to a 1.83% rally in NIFTY and a 6.71% fall in the Nifty FMCG index. Tata Consumer Products Ltd is down for a fifth straight session today. The stock is quoting at Rs 1073.7, down 0.29% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.45% on the day, quoting at 25036.9. The Sensex is at 82130.42, down 0.45%.Tata Consumer Products Ltd has lost around 0.9% in last one Nifty FMCG index of which Tata Consumer Products Ltd is a constituent, has increased around 2.12% in last one month and is currently quoting at 55910.25, up 0.23% on the day. The volume in the stock stood at 4.88 lakh shares today, compared to the daily average of 11.12 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1076.6, down 0.41% on the day. Tata Consumer Products Ltd tumbled 5.38% in last one year as compared to a 1.83% rally in NIFTY and a 6.71% fall in the Nifty FMCG index. The PE of the stock is 89.07 based on TTM earnings ending March 25.


Business Standard
25 minutes ago
- Business Standard
Mankind Pharma Ltd spurts 2.92%, gains for five straight sessions
Mankind Pharma Ltd is quoting at Rs 2653.7, up 2.92% on the day as on 12:44 IST on the NSE. The stock is up 23.51% in last one year as compared to a 1.91% gain in NIFTY and a 7.81% gain in the Nifty Pharma. Mankind Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 2653.7, up 2.92% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 25055.85. The Sensex is at 82161.62, down 0.41%. Mankind Pharma Ltd has added around 11.97% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has added around 1.97% in last one month and is currently quoting at 22225.9, up 1.11% on the day. The volume in the stock stood at 10.75 lakh shares today, compared to the daily average of 7.73 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2660.3, up 3.07% on the day. Mankind Pharma Ltd is up 23.51% in last one year as compared to a 1.91% gain in NIFTY and a 7.81% gain in the Nifty Pharma index. The PE of the stock is 56.47 based on TTM earnings ending March 25.


Business Standard
26 minutes ago
- Business Standard
Glenmark Pharmaceuticals Ltd up for third consecutive session
Glenmark Pharmaceuticals Ltd is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The stock is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in the Nifty Pharma index. Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 25050.1. The Sensex is at 82139.43, down 0.44%. Glenmark Pharmaceuticals Ltd has gained around 31.56% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2% in last one month and is currently quoting at 22225.9, up 1.15% on the day. The volume in the stock stood at 27.13 lakh shares today, compared to the daily average of 18.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2223, up 1.92% on the day. Glenmark Pharmaceuticals Ltd is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in the Nifty Pharma index. The PE of the stock is 35.29 based on TTM earnings ending March 25.